Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer’s Patients
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on neuroscience, today reported initiation of a Phase 2b study of its lead drug candidate, PTI-125, in Alzheimer’s patients. PTI-125 is a small molecule that targets the massive neuroinflammation and neurodegeneration observed in the Alzheimer’s brain. In conjunction with the initiation of this Phase 2b study, Cassava Sciences also reported dosing of the first two patients for this study, both of which were uneventful. This Phase 2b study is supported by a research grant award from the National Institutes of Health (NIH). “There is a profound and timely need to develop new drug therapies for this devastating disease,” said Remi Barbier, President & CEO. “We are pleased to advance PTI-125 into this ran
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- Redemption Date Announced for Warrants [Yahoo! Finance]Yahoo! Finance
- Redemption Date Announced for WarrantsGlobeNewswire
- CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- DEADLINE TODAY: The Schall Law Firm Encourages Investors in Cassava Sciences, Inc. with Losses of $100,000 to Contact the FirmGlobeNewswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVAAccesswire
SAVA
Earnings
- 2/28/24 - Miss
SAVA
Analyst Actions
- 3/5/24 - HC Wainwright
SAVA
Sec Filings
- 4/22/24 - Form 4
- 4/17/24 - Form 4
- 4/15/24 - Form 8-K
- SAVA's page on the SEC website